drugset

drugset / Trial / NCT03257358

A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod

NCT03257358 ↗

Phase 4 Completed 382 enrolled Novartis Pharmaceuticals

Non-randomizedParallel-groupOpen-labelBasic science

Summary

A study of immune phenotype biomarkers in patients with Relapsing Multiple Sclerosis (RMS) after treatment with 0.5mg fingolimod

Timeline

Start: 2017-09-19
Primary completion: 2019-03-05
Completion: 2019-06-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fingolimod	Small molecule	0.5 mg	Oral

Indications